Please login to the form below

Not currently logged in

FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments

The company confirmed that six other phase 2 trials would go ahead as previously planned


Gilead Sciences has shared that the US Food and Drug Administration (FDA) has placed a partial clinical hold on three phase 3 trials assessing the combination of magrolimab plus azacitidine used for patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and AML patients unable to receive intensive chemotherapy.

The partial hold was also applied to earlier stage studies for MDS and myeloid malignancies. The company confirmed that six other phase 2 trials would go ahead as previously planned and also stated that tests evaluating magolimab in isolation, without azacitidine or in combination with other drugs, remain unaffected by the latest decision.

Gilead said that the partial hold on the clinical trials was due to the FDA’s decision to act in the interest of patient safety, with concerns over an apparent imbalance in reported suspected unexpected serious adverse reactions (SUSARs) between branches of the study.

"The safety and well-being of people enrolled in our studies is our top priority. We will share more information with the medical and patient community as soon as we can,” said Merdad Parsey, chief medical officer at Gilead Sciences.

Despite the company being unable to identify any specific adverse reactions or negative safety markers, it has been decided that the partial clinical hold will be implemented by Gilead companywide regarding all ongoing combination studies of magrolimab and azacitidine.

For participants already enrolled in the clinical studies, close monitoring according to study protocol will be carried out, with the participants continuing to receive magrolimab and azacitidine, or a placebo.

Gilead is in the process of gathering additional data analyses in order to address the issues raised by the FDA, alongside company efforts to notify clinical investigatory teams and regulatory authorities worldwide about the clinical hold.

Parsey continued: “We remain confident in the potential of magrolimab across a broad range of tumours, including the other, ongoing magrolimab studies. We are grateful to those participating in our studies, their families, and the investigators for their continued contributions to the clinical programme for magrolimab.”

Gilead is continuing to work with regulators, with the aim to decide the best course of action in removing the partial hold on the studies impacted.

Speaking on the company’s commitment to developing new MDS therapies, Parsey said: “Considering the high unmet need for new medicines in myelodysplastic syndrome and acute myeloid leukemia, we will work closely with regulatory authorities worldwide to continue the magrolimab development programme appropriately.”

Article by
Fleur Jeffries

27th January 2022

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...